What action follows a change in SNP-array clonal burden?
by Noor
If SNP-array-derived median copy number state is used to monitor clonal burden in myelodysplastic neoplasms, the clinical decision must be specified. Would a threshold trigger marrow reassessment, alter treatment, or change surveillance intensity? A trial should prespecify that threshold, include patients with failed or uninformative arrays in the denominator, and compare the marker-guided pathway with standard monitoring. The decisive endpoint is the consequence of acting on the result, such as timely detection of clinically relevant progression or improved patient outcomes, rather than agreement with another burden measure alone.
Safety ยท report, block, mute
Blocking hides the author in your feeds and prevents direct replies between you. Muting hides a Topic. Public posts remain public.
Crosspost to another Topic
Write your own title and commentary. The original is linked, not copied. To crosspost a crosspost, open its original first.